The Power of Dual Immunotherapy - Seite 2

"We believe that immunostimulatory therapies may show promise when used in combination with existing therapies that overcome immune inhibition. We are well positioned to bring these types of dual immunotherapy regimens forward," said Gary Grossfeld, Global Development Project Leader at Bristol Myers Squibb. "Leveraging more than one pathway can potentially improve the immune system response to cancer, thereby building on the efficacy of single agent therapy while maintaining a favorable safety profile."

The importance of precision medicine

Part of bringing new therapies forward is ensuring that they are targeted to specific diseases and patient populations.

Certain biomarkers - whether genetic or protein based - may give an indication that one type of therapy or combination will work better in some patients versus others.

"Our study protocols are filled with exploratory biomarker work aimed at understanding which patients are likely to benefit from certain treatments. We are dedicated to a precision medicine approach in our development programs, and I expect we may see great progress in the next several years," said Grossfeld.

Grossfeld believes that a focus on precision medicine, as well as a strategic approach to building on existing therapies with investigational agents, have positioned Bristol Myers Squibb at the forefront of immuno-oncology research. Despite advances in treatment of cancer with immunotherapy, a large number of unmet clinical needs remain. The goal is always to move the needle for patients.

Foto: Accesswire

View additional multimedia and more ESG storytelling from Bristol Myers Squibb Company on 3blmedia.com.

Contact Info:
Spokesperson: Bristol Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: [e-mail]

SOURCE: Bristol Myers Squibb Company

View source version on accesswire.com:
https://www.accesswire.com/737055/The-Power-of-Dual-Immunotherapy


The Bristol-Myers Squibb Stock at the time of publication of the news with a fall of -0,10 % to 72,92EUR on NYSE stock exchange (27. Januar 2023, 15:42 Uhr).